Arbutus Biopharma

In News

FDA grants Arbutus Biopharma drug fast track designation - Pennsylvania Business Report -

Pennsylvania Business Report - - Apr 21, 2026

Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability - Yahoo Finance

Yahoo Finance - Apr 17, 2026

Arbutus Biopharma Corp ($ABUS) Former Interim President and CEO 2025 Pay Revealed - Quiver Quantitative

Quiver Quantitative - Apr 15, 2026

[8-K] Arbutus Biopharma Corp Reports Material Event - Stock Titan

Stock Titan - Apr 15, 2026

Whitefort Capital Management, LP Increases Stake in Arbutus Biop - GuruFocus

GuruFocus - Apr 17, 2026

Warminster-Founded Arbutus Biopharma to Receive $190M in Moderna Settlement - BUCKSCO.Today

BUCKSCO.Today - Mar 09, 2026

Arbutus shares jump after FDA grants fast track status to hepatitis B therapy - MSN

MSN - Apr 18, 2026

Arbutus Biopharma (ABUS) Stock Analysis: Unveiling an 11.5% Upside in the Biotech Sector - DirectorsTalk Interviews

DirectorsTalk Interviews - Apr 17, 2026

Arbutus wins FDA fast track tag for lead asset (ABUS:NASDAQ) - Seeking Alpha

Seeking Alpha - Apr 15, 2026

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B - GlobeNewswire

GlobeNewswire - Apr 15, 2026

Arbutus Biopharma Gains FDA Fast Track for Imdusiran - TipRanks

TipRanks - Apr 15, 2026

Chardan reiterates Arbutus Biopharma stock rating on Moderna deal - Investing.com

Investing.com - Mar 04, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment